Literature DB >> 7716711

Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.

G Valesini1, R Priori, A Francia, G Balestrieri, A Tincani, P Airo, R Cattaneo, A Zambruni, B Troianello, M Chofflon.   

Abstract

In systemic lupus erythematosus (SLE), neurological involvement has been reported to occur with frequencies ranging from 14% (severe cases) to 83% (mild forms included). In spite of early diagnosis and aggressive treatment, neuropsychiatric SLE may represent a serious problem of management. We describe three cases, one with acute transverse myelitis, one with hemiparesis, and one with signs of focal and diffuse cerebral dysfunction, in whom improvement following intrathecal therapy with methotrexate and dexamethasone was observed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7716711     DOI: 10.1007/bf00197524

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  36 in total

Review 1.  Autoantibodies in central nervous system lupus.

Authors:  E M Hay; D A Isenberg
Journal:  Br J Rheumatol       Date:  1993-04

2.  Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies.

Authors:  R A Asherson; D Mercey; G Phillips; N Sheehan; A E Gharavi; E N Harris; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-08       Impact factor: 19.103

3.  Systemic lupus erythematosus presenting with neurological disorders.

Authors:  M R Tola; E Granieri; L Caniatti; E Paolino; C Monetti; L Dovigo; R Scolozzi; P De Bastiani; M Carreras
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

Review 4.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 5.  Acute transverse myelopathy complicating systemic lupus erythematosus.

Authors:  D J Propper; R C Bucknall
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

6.  Neurological manifestations of systemic lupus erythematosus: role of antiphospholipid antibodies.

Authors:  M Golstein; O Meyer; P Bourgeois; E Palazzo; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Exp Rheumatol       Date:  1993 Jul-Aug       Impact factor: 4.473

7.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.

Authors:  F M Balis; C M Lester; G P Chrousos; R L Heideman; D G Poplack
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

Review 8.  The pharmacology of methotrexate.

Authors:  E A Olsen
Journal:  J Am Acad Dermatol       Date:  1991-08       Impact factor: 11.527

9.  Reflex seizures as initial manifestations of systemic lupus erythematosus in childhood.

Authors:  M Brinciotti; G Ferrucci; G Trasatti; R Priori; E Squilloni; G Valesini
Journal:  Lupus       Date:  1993-08       Impact factor: 2.911

10.  Spinal cord involvement in systemic lupus erythematosus.

Authors:  H J Hachen; A Chantraine
Journal:  Paraplegia       Date:  1979-09
View more
  12 in total

1.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors:  L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

2.  Chemosis as a presenting symptom of systemic lupus erythematosus.

Authors:  V Peponis; S Chalkiadakis; S Ergin; V C Kyttaris
Journal:  Lupus       Date:  2010-07       Impact factor: 2.911

Review 3.  Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature.

Authors:  B Kovacs; T L Lafferty; L H Brent; R J DeHoratius
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

Review 4.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

5.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors:  Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2006-11-15       Impact factor: 19.103

Review 6.  Autoimmune disorders: a concept of treatment based on mechanisms of disease.

Authors:  Peter A Miescher; Laura Zavota; Alejandra Ossandon; Bruno Lagana
Journal:  Springer Semin Immunopathol       Date:  2003-11-06

Review 7.  Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options.

Authors:  Christian Michael Hedrich; Hildegard Zappel; Simon Straub; Martin W Laass; Kathrin Wieczorek; Gabriele Hahn; Georg Heubner; Manfred Gahr
Journal:  Clin Rheumatol       Date:  2010-10-01       Impact factor: 3.650

8.  Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice.

Authors:  Jiali Zhu; Kui Cui; Jianqun Kou; Shuzhi Wang; Yinli Xu; Zhihui Ding; Rong Han; Zhenghong Qin
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-30       Impact factor: 2.629

Review 9.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

10.  A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: a case report.

Authors:  Dongmei Wang; Yongming Wu; Zhong Ji; Shengnan Wang; Yunqi Xu; Kaibin Huang; Yu Peng; Hui Zheng; Honghao Wang; Xiaomei Zhang; Suyue Pan
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.